Electrophysiological assessments of psychiatric disorders have produced a number of promising, highly replicable findings and thus carry the potential of becoming clinically utilizable in the diagnostic or prognostic evaluation of psychopathological conditions. The procedures involved are rather complex technically and the interpretation of the findings require a combined neurophysiological and clinical expertise. On the other hand, electrophysiological techniques are in general non-invasive and relatively inexpensive, and neurophysiology laboratories are widely available in the clinical setting.
Among these techniques, event-related potentials (ERPs) are of major interest in psychiatry, particularly since these tools can indicate cortical neuronal dysfunctions, which play a major role in various neuropsychiatric disorders.
WalterWGCooperRAldridgeVJMcCallumWCWinterALContingent negative nariation: An electric sign of sensorimotor association and expectancy in the human brain. Nature1964;203:380–384.
2.
SuttonSBrarenMZubinJJohnEREvoked-potential correlates of stimulus uncertainty. Science1965;150(700): 1187–1188.
3.
VerlegerR.Event related potentials and cognition: A critique of the context updating hypothesis and an alternative interpretation of P3. Behav Br Sci1988;11:343–356.
4.
HalgrenEBaudenaPClarkeJMHeitGLiegeoisCChauvelPIntracerebral potentials to rare target and distractor auditory and visual stimuli. I. Superior temporal plane and parietal lobe. Electroencephalogr Clin Neuro-physiol1995;94(3): 191–220.
5.
HalgrenEBaudenaPClarkeJMHeitGMarinkovicKDevauxBIntracerebral potentials to rare target and distractor auditory and visual stimuli. II. Medial, lateral and posterior temporal lobe. Electroencephalogr Clin Neuro-physiol1995;94(4): 229–250.
6.
BaudenaPHalgrenEHeitGClarkeJMIntracerebral potentials to rare target and distractor auditory and visual stimuli. III. Frontal cortex. Electroencephalogr Clin Neuro-physiol1995;94(4): 251–264.
7.
MulertCJagerLSchmittRBussfeldPPogarellOMollerHJIntegration of fMRI and simultaneous EEG: Towards a comprehensive understanding of localization and time-course of brain activity in target detection. Neuroimage2004;22(1): 83–94.
8.
DierksTFrolichLIhlRMaurerK.Event-related potentials and psychopharmacology: Cholinergic modulation of P300. Pharmacopsychiatry1994;27(2): 72–74.
9.
AntalABodis-WollnerIGhilardiMFGloverAMylinLToldiJ.The effect of levo-acetyl-carnitine on visual cognitive evoked potentials in the behaving monkey. Electroencephalogr Clin Neurophysiol1993;86(4): 268–274.
10.
BrandeisDNaylorHHallidayRCallawayEYanoL.Scopolamine effects on visual information processing, attention, and event-related potential map latencies. Psycho-physiology1992;29(3): 315–336.
11.
MeadorKJCholinergic, serotonergic, and GABAergic effects on the ERP. Electroencephalogr Clin Neurophysiol (suppl)1995;44:151–155.
12.
MeadorKJLoringDWDavisHCSethiKDPatelBRAdamsRJCholinergic and serotonergic effects on the P3 potential and recent memory. J Clin Exp Neuropsychol1989;11(2): 252–260.
13.
HarrisonJBBuchwaldJSKagaKWoolfNJButcherLL“Cat P300” disappears after septal lesions. Electroencephalogr Clin Neurophysiol1988;69(1): 55–64.
14.
HammondEJMeadorKJAung-DinRWilderBJCholinergic modulation of human P3 event-related potentials. Neurology1987;37(2): 346–350.
15.
CallawayEHallidayRNaylorHSchechterG.Effects of oral scopolamine on human stimulus evaluation. Psycho-pharmacology (Berl)1985;85(2): 133–138.
16.
PinedaJAFooteSLNevilleHJEffects of locus coeruleus lesions on auditory, long-latency, event-related potentials in monkey. J Neurosci1989;9(1): 81–93.
17.
BlumKBravermanERDinardoMJWoodRCSheridanPJProlonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. Pharmacogenetics1994;4(6): 313–322.
18.
NobleEPBermanSMOzkaragozTZRitchieT.Prolonged P300 latency in children with the D2 dopamine receptor A1 allele. Am J Hum Genet1994;54(4): 658–668.
19.
GallinatJBajboujMSanderTSchlattmannPXuKFerroEFAssociation of the G1947A COMT (Val (108/158) Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry2003;54(1): 40–48.
20.
PritchardWSRazNAugustGJNo effect of chronic fenfluramine on the P300 component of the event-related potential. Int J Neurosci1987;35(1–2): 105–110.
21.
ShutaraYKogaYFujitaKTakeuchiHMochidaMTakemasaK.An event-related potential study on the impairment of automatic processing of auditory input in schizophrenia. Brain Topogr1996;8(3): 285–289.
22.
RaoKMAnanthnarayananCVGangadharBNJanakiramaiahN.Smaller auditory P300 amplitude in schizophrenics in remission. Neuropsychobiology1995;32(3): 171–174.
23.
FordJMWhitePLimKOPfefferbaumA.Schizophrenics have fewer and smaller P300s: A single-trial analysis. Biol Psychiatry1994;35(2): 96–103.
24.
LaurentAGarcia-LarreaLDaleryJTerraJLD'AmatoTMarie-CardineMThe P 300 potential in schizophrenia. [In French] Encephale1993;19(3): 221–227.
25.
EikmeierGLodemannEZerbinDGastparM.Event-related potentials in schizophrenic patients in the acute phase and in remission. [In German] EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb1991;22(1): 15–20.
26.
BlackwoodDHSt ClairDMMuirWJDuffyJCAuditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Arch Gen Psychiatry1991;48(10): 899–909.
27.
JuckelGMuller-SchubertAGaebelWHegerlU.Residual symptoms and P300 in schizophrenic outpatients. Psychiatry Res1996;65(1): 23–32.
28.
SchreiberHStolz-BornGKornhuberHHBornJ.Event-related potential correlates of impaired selective attention in children at high risk for schizophrenia. Biol Psychiatry1992;32(8): 634–651.
29.
MurrayRMO'CallaghanECastleDJLewisSWAneurode-velopmental approach to the classification of schizophrenia. Schizophr Bull1992;18(2): 319–332.
30.
HegerlUJuckelGMuller-SchubertAPietzckerAGaebelW.Schizophrenics with small P300: A subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia?Acta Psychiatr Scand1995;91(2): 120–125.
31.
StrikWKDierksTFranzekEMaurerKBeckmannH.Differences in P300 amplitudes and topography between cycloid psychosis and schizophrenia in Leonhard's classification. Acta Psychiatr Scand1993;87(3): 179–183.
32.
StrikWKDierksTMaurerK.Amplitudes of auditory P300 in remitted and residual schizophrenics: Correlations with clinical features. Neuropsychobiology1993;27(1): 54–60.
33.
StrikWKFallgatterAJStoeberGFranzekEBeckmannH.Specific P300 features in patients with cycloid psychosis. Acta Psychiatr Scand1996;94(6): 471–476.
34.
BlackwoodD.P300, a state and a trait marker in schizophrenia. Lancet2000;355(9206); 771–772.
35.
MathalonDHFordJMPfefferbaumA.Trait and state aspects of P300 amplitude reduction in schizophrenia: A retrospective longitudinal study. Biol Psychiatry2000;47(5): 434–449.
36.
Frodl-BauchTGallinatJMeisenzahlEMMollerHJHegerlU.P300 subcomponents reflect different aspects of psychopathology in schizophrenia. Biol Psychiatry1999;45(1): 116–126.
37.
SantoshPJMalhotraSRaghunathanMMehraYNA study of P300 in melancholic depression-correlation with psychotic features. Biol Psychiatry1994;35(7): 474–479.
38.
BruderGEToweyJPStewartJWFriedmanDTenkeCQuitkinFMEvent-related potentials in depression: Influence of task, stimulus hemifield and clinical features on P3 latency. Biol Psychiatry1991;30(3): 233–246.
39.
HansenneMPitchotWGonzalezMoreno AZalduaIUAnsseauM.Suicidal behavior in depressive disorder: An event-related potential study. Biol Psychiatry1996;40(2): 116–122.
40.
PolichJLadishCBloomFEP300 assessment of early Alzheimer's disease. Electroencephalogr Clin Neurophysiol1990;77(3): 179–189.
41.
PfefferbaumAFordJMKraemerHCClinical utility of long latency “cognitive” event-related potentials (P3): The cons. Electroencephalogr Clin Neurophysiol1990;76(1): 6–12; discussion 1.
42.
FrodlTHampelHJuckelGBurgerKPadbergFEngelRRValue of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology2002;39(2): 175–181.
43.
ThomasAIaconoDBonanniLD'AndreamatteoGOnofrjM.Donepezil, rivastigmine, and vitamin E in Alzheimer disease: A combined P300 event-related potentials/neuropsy-chologic evaluation over 6 months. Clin Neuropharmacol2001;24(1): 31–42.
44.
OnofrjMThomasALucianoALIaconoDDi RolloAD'AndreamatteoGDonepezil versus vitamin E in Alzheimer's disease: II. mild versus moderate-severe Alzheimer's disease. Clin Neuropharmacol2002;25(4): 207–215.
45.
PogarellOSchulzCJuckelGMueller-SiechenederFLauxGBahraRAuditory evoked P300 and treatment response to donepezil in patients with Alzheimer's disease. World J Biol Psychiatry2001;2:264.
46.
RockstrohBMullerMWagnerMCohenRElbertT.Event-related and motor responses to probes in a forewarned reaction time task in schizophrenic patients. Schizophr Res1994;13(1): 23–34.
47.
WagnerMRendtorffNKathmannNEngelRRCNV, PINV and probe-evoked potentials in schizophrenics. Electroencephalogr Clin Neurophysiol1996;98(2): 130–143.
48.
KornhuberHHDeeckeL.Changes in the brain potential in voluntary movements and passive movements in man: Readiness potential and reafferent potentials. Pflugers Arch Gesamte Physiol Menschen Tiere1965;284:1–17.
49.
AshtonCHMarshallEFHassanyehFMarshVRWright-HonariS.Biological correlates of deliberate self-harm behaviour: A study of electroencephalographic, biochemical and psychological variables in parasuicide. Acta Psychiatr Scand1994;90(5): 316–323.
50.
JavittDCSteinschneiderMSchroederCEVaughanHGJr.ArezzoJC. Detection of stimulus deviance within primate primary auditory cortex: Intracortical mechanisms of mismatch negativity (MMN) generation. Brain Res1994;667(2): 192–200.
51.
JavittDCSchroederCESteinschneiderMArezzoJCRitterWVaughanHGJr.. Cognitive event-related potentials in human and non-human primates: Implications for the PCP/NMDA model of schizophrenia. Electroencephalogr Clin Neurophysiol1995; (suppl) 44: 161–175.
52.
SerraJMEsceraCSanchez-TuretMSanchez-SastreJGrauC.The H1-receptor antagonist chlorpheniramine decreases the ending phase of the mismatch negativity of the human auditory event-related potentials. Neurosci Lett1996;203(2): 77–80.
53.
JavittDCDoneshkaPGrochowskiSRitterW.Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry1995;52(7): 550–558.
54.
CattsSVShelleyAMWardPBLiebertBMcConaghyNAndrewsSBrain potential evidence for an auditory sensory memory deficit in schizophrenia. Am J Psychiatry1995;152(2): 213–219.
55.
ShelleyAMWardPBCattsSVMichiePTAndrewsSMcConaghyN.Mismatch negativity: An index of a preattentive processing deficit in schizophrenia. Biol Psychiatry1991;30(10): 1059–1062.
56.
RosburgTKreitschmann-AndermahrISauerH.Mismatch negativity in schizophrenia research. An indicator of early processing disorders of acoustic information. [In German] Nervenarzt2004;75(7): 633–641.
57.
BaldewegTKlugmanAGruzelierJHirschSRMismatch negativity potentials and cognitive impairment in schizophrenia. Schizophr Res2004;69(2–3): 203–217.
58.
LightGABraffDLMismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry2005;62(2): 127–136.
59.
Brockhaus-DumkeATendolkarIPukropRSchultze-LutterFKlosterkotterJRuhrmannS.Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr Res2005;73(2–3): 297–310.
60.
AdlerLEOlincyAWaldoMHarrisJGGriffithJStevensKSchizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull1998;24(2): 189–202.
61.
PotterDSummerfeltAGoldJBuchananRWReview of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull2006;32(4): 692–700.
62.
AdlerLEWaldoMCFreedmanR.Neurophysiologic studies of sensory gating in schizophrenia: Comparison of auditory and visual responses. Biol Psychiatry1985;20(12): 1284–1296.
63.
SiegelCWaldoMMiznerGAdlerLEFreedmanR.Deficits in sensory gating in schizophrenic patients and their relatives: Evidence obtained with auditory evoked responses. Arch Gen Psychiatry1984;41(6): 607–612.
64.
LeonardSGaultJHopkinsJLogelJVianzonRShortMAssociation of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry2002;59(12): 1085–1096.
LeonardSGaultJAdamsCBreeseCRRollinsYAdlerLENicotinic receptors, smoking and schizophrenia. Restor Neurol Neurosci1998;12(2–3): 195–201.
67.
LeonardSAdamsCBreeseCRAdlerLEBickfordPByerleyWNicotinic receptor function in schizophrenia. Schizophr Bull1996;22(3): 431–445.
68.
FreedmanRAdlerLEBickfordPByerleyWCoonHCullumCMSchizophrenia and nicotinic receptors. Harv Rev Psychiatry1994;2(4): 179–192.
69.
NagamotoHTAdlerLEHeaRAGriffithJMMcRaeKAFreedmanR.Gating of auditory P50 in schizophrenics: Unique effects of clozapine. Biol Psychiatry1996;40(3): 181–188.
70.
FreedmanRAdlerLEWaldoMCPachtmanEFranksRDNeurophysiological evidence for a defect in inhibitory pathways in schizophrenia: Comparison of medicated and drug-free patients. Biol Psychiatry1983;18(5): 537–551.
71.
NagamotoHTAdlerLEMcRaeKAHuettlPCawthraEGerhardtGAuditory P50 in schizophrenics on clozapine: Improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology1999;39(1): 10–17.
72.
AdlerLEOlincyACawthraEMMcRaeKAHarrisJGNagamotoHTVaried effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry2004;161(10): 1822–1828.
73.
Myles-WorsleyMOrdLBlailesFNgiralmauHFreedmanR.P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia. Biol Psychiatry2004;55(7): 663–667.
74.
WaldoMCCareyGMyles-WorsleyMCawthraEAdlerLENagamotoHTCodistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res1991;39(3): 257–268.
75.
ClementzBAGeyerMABraffDLPoor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry1998;155(12):1691–1694.
76.
FreedmanROlincyARossRGWaldoMCStevensKEAdlerLEThe genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep2003;5(2):155–161.
77.
BuchsbaumMSilvermanJ.Stimulus intensity control and the cortical evoked response. Psychosom Med1968;30(1): 12–22.
78.
ConnollyJFGruzelierJHAmplitude and latency changes in the visual evoked potential to different stimulus intensities. Psychophysiology1982;19(6): 599–608.
79.
DragutinovichS.Measurement and definition of changes in the visual evoked potential to different stimulus intensities. Int J Psychophysiol1987;5(2): 125–133.
80.
Carrillo-de-la-PenaMTERP augmenting/reducing and sensation seeking: A critical review. Int J Psychophysiol1992;12(3): 211–220.
81.
HegerlUGallinatJJuckelG.Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?J Affect Disord2001;62(1–2): 93–100.
82.
JuckelGCsepeVMolnarMHegerlUKarmosG.Intensity dependence of auditory evoked potentials in behaving cats. Electroencephalogr Clin Neurophysiol1996;100(6): 527–537.
83.
JuckelGHegerlUMolnarMCsepeVKarmosG.Auditory evoked potentials reflect serotonergic neuronal activity—a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsycho-pharmacology1999;21(6): 710–716.
84.
NaatanenRPictonT.The N1 wave of the human electric and magnetic response to sound: A review and an analysis of the component structure. Psychophysiology1987;24(4): 375–425.
85.
HegerlUGallinatJMrowinskiD.Intensity dependence of auditory evoked dipole source activity. Int J Psychophysiol1994;17(1): 1–13.
86.
BrechmannABaumgartFScheichH.Sound-level-dependent representation of frequency modulations in human auditory cortex: A low-noise fMRI study. J Neurophysiol2002;87(1): 423–433.
87.
MulertCJagerLProppSKarchSLeichtGPogarellOLoudness dependence of the primary auditory cortex as an indicator of central serotonergic transmission: Combination of EEG and fMRI. Neuroimage2004;22:(suppl 1), TU356.
88.
TuchtenhagenFDaumannJNorraCGobbeleRBeckerSPelzSHigh intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychophar-macology2000;22(6): 608–617.
89.
CroftRJKlugmanABaldewegTGruzelierJHElectrophysiological evidence of serotonergic impairment in long-term MDMA (“ecstasy”) users. Am J Psychiatry2001;158(10):1687–1692.
90.
NorraCMrazekMTuchtenhagenFGobbeleRBuchnerHSassHEnhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. J Psychiatr Res2003;37(1): 23–33.
91.
HegerlUJuckelG.Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis. Biol Psychiatry1993;33(3): 173–187.
92.
MulertCJuckelGAugustinHHegerlU.Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clin Neurophysiol2002;113(10): 1566–1572.
93.
GallinatJBottlenderRJuckelGMunke-PuchnerAStotzGKussHJThe loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl)2000;148(4): 404–411.
94.
PogarellOTatschKJuckelGHamannCMulertCPopperlGSerotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. Neuropsychopharmacology2004;29(10):1910–1917.
95.
GallinatJSenkowskiDWernickeCJuckelGBeckerISanderTAllelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. Neuropsychopharmacology2003;28(3): 530–532.
96.
PogarellOPoepperlGMulertCHamannCSadowskyNRiedelMSERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacology. In press.
97.
PaigeSRFitzpatrickDFKlineJPBaloghSEHendricksSEEvent-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology1994;30(4): 197–201.
98.
PaigeSRHendricksSEFitzpatrickDFBaloghSBurkeWJAmplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. Psychopharmacol Bull1995;31(2): 243–248.
99.
Muller-OerlinghausenB.Lithium long-term treatment—does it act via serotonin?Pharmacopsychiatry1985;18(2): 214–217.
100.
BaronMGershonESRudyVJonasWZBuchsbaumM.Lithium carbonate response in depression: Prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. Arch Gen Psychiatry1975;32(9): 1107–1111.
101.
BuchsbaumMGoodwinFMurphyDBorgeG.AER in affective disorders. Am J Psychiatry1971;128(1): 19–25.
102.
McKnewDHCytrynLBuchsbaumMSHamovitJLamourMRapoportJLLithium in children of lithium-responding parents. Psychiatry Res1981;4(2): 171–180.
103.
HegerlUUlrichGMuller-OerlinghausenB.Auditory evoked potentials and response to lithium prophylaxis. Pharmacopsychiatry1987;20(5): 213–216.
104.
HegerlUWulffHMuller-OerlinghausenB.Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: A replication study. Psychiatry Res1992;44(3): 181–190.
